Biologic drugs are well established treatments for a wide range of disorders, and many of these medicines have become blockbuster products. But currently available biologics still have limitations, ...

Biologics are complex medications produced through biological processes or from living organisms such as proteins and genes. Biosimilars are what they sound like — similar to, but not the same as, an ...

Tremfya interacts with other biologic immunomodulator drugs, such as abatacept (Orencia) and canakinumab (Ilaris). Tremfya can also interact with tricyclic antidepressants (TCAs), such as ...

Rystiggo (rozanolixizumab-noli) is a prescription drug that’s used to treat myasthenia gravis. This drug can interact with certain other medications. For example, Rystiggo can interact with monoclonal ...

It’s becoming more common to treat Crohn’s disease with 2 biologic medications, or a biologic and a small molecule drug. Find ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

The Trump administration’s latest effort to lower drug costs is expanding to biosimilars, medications that are highly similar to biologic drugs made with or isolated from living organisms such as ...

Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US. In 2009, Congress created a regulatory pathway for ...

The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare as breakthroughs in immunotherapy, regenerative medicine, cell engineering, and AI-assisted ...